TIDMVLG
Venture Life Group PLC
17 July 2019
17 July 2019
Venture Life Group plc
("Venture Life" or the "Group")
Commercial update
Increased product distribution and new international partnership
agreements
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the UK and
international self-care market, announces a commercial update on
business developments in H1 2019.
Own Brand Update
The Company continues to be successful in expanding the reach of
its brand portfolio. The Group launched products with 11
international partners in H1 2019, as part of its continued
international market expansion, with highlights including:
Dentyl
Good progress has been achieved in expanding the Dentyl brand
both internationally and domestically since it was acquired in
August 2018. As a result, Dentyl is now available in 7 markets,
including the UK and Ireland, compared with 4 markets
pre-acquisition. Highlights include a new 5-year distribution
agreement with an existing Chinese partner to add the Dentyl Fresh
Breath Beads to their Dentyl range across mainland China in Q3
2019.
In the UK, Lloyds Pharmacy, one of the UK's largest pharmacy
chains will be supplying the 500ml Dentyl Fresh Clove flavoured
mouthwash from September 2019. This is the first time Dentyl has
been distributed by Lloyds Pharmacy as part of their planogram.
Additionally, Superdrug, one of the largest health and beauty
retailers in the UK has increased distribution of Dentyl 500ml
mouthwash by 27% since January 2019, and 93% since brand
acquisition, and as a result from July 2019, Dentyl will be
available in 385 stores.
UltraDEX
Success for the UltraDEX oral care brand continues with two new
partnerships; with ASDA grocery chain and Well Pharmacy. Part of
the Walmart retail corporation, ASDA has confirmed the launch of
UltraDEX mouthwash and Fresh Breath Spray. Well Pharmacy, the third
largest pharmacy chain in the UK (after Boots and Superdrug) will
stock the UltraDEX range. Both retailers will supply UltraDEX from
September 2019.
Superdrug has also confirmed the launch of UltraDEX Whitening
mouthwash from July 2019 in 94% of its stores. UltraDEX One Go
sachets will also be launched for the first time in Italy and the
UAE in late 2019/early 2020, with existing partners. UltraDEX
products are now available in 20 markets, including the UK and
Ireland.
Myco ClearÔ, Vonalei and Procto-eze Plus
Myco Clear has been launched in Portugal with Jaba Recordati and
more recently with a partner in France. Separately, Procto-eze Plus
and vonalei has been launched in Israel with Taro Pharmaceuticals
in H1 2019.
Manufacturing Division
A long-term manufacturing agreement has been signed on a
well-established range of oral care products with an international
partner. Products include mouthwashes, toothpastes and gels for the
EU, Asia and Australia; development is underway and first
production is expected to finish by the end of 2019.
An agreement has also been signed with Athena Cosmetics
Corporation, USA, to manufacture two cosmetic products. First
production will commence from August 2019 and a second
manufacturing order is expected before the end of 2019.
A new agreement with Italian pharmaceutical company Giellepi
S.P.A will see the development and manufacturing of a new Medical
Device commence at the end of 2019.
Finally, a new agreement has been signed with AlfaSigma, Italy,
to manufacture a cosmetic product. Development is due to finish in
October 2019, with first production expected by the end of
2019.
UK digital marketing campaign
The Group's 2019 UK marketing strategy for both UltraDEX and
Dentyl is predominately digitally focused and targeting various
social media channels.
In the case of UltraDEX, the current #youneverknow campaign
features a series of videos, introducing an element of humour,
encouraging consumers to talk about bad breath and engage through
social media channels. This is being supported with a 10-day
sampling campaign commencing 17 July 2019, whereby over 80,000 free
mouthwash sachets will be distributed at central London locations.
In addition to this, the #spititout campaign is underway and being
received well by both consumers and the UK retail trade, which
indicates that the social media marketing strategy is both
effective and helping to raise brand awareness.
London Stock Exchange's 1000 Companies to Inspire Britain
2019
For the fourth consecutive year, the Group has been included in
the list, which is reserved for companies significantly
outperforming its peers. Companies are required to record
consistent revenue growth over a minimum of three years to qualify
for the list.
Jerry Randall, CEO of Venture Life Group, said: "I am pleased to
report continued commercial progress in H1 2019, particularly the
11 new product launches with partners and securing the ASDA and
Well Pharmacy distribution for UltraDEX, as well as building on the
international distribution in China for the Dentyl brand. This is
also the fourth consecutive year that we have been featured in
'1000 Companies to Inspire Britain', which is an exceptional
achievement and testament to our year on year growth, which in 2018
saw the Group become earnings positive for the first time. This has
been a great result for the whole team at Venture Life,
particularly at this challenging time in consumer markets."
For further information, please contact:
+44 (0) 1344
Venture Life Group PLC 578004
Jerry Randall, Chief Executive Officer
+44 (0) 20 7397
Cenkos Securities Ltd (Nomad and Broker) 8900
Mark Connelly / Stephen Keys / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Alma PR venturelife@almapr.co.uk or + 44 (0)
203 405 0208
Helena Bogle / Hilary Buchanan
/ Jessica Joynson
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for maintaining brain function, medical devices for
women's intimate healthcare and proctology and dermo-cosmetics for
addressing the signs of ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABUGDRCUBBGCL
(END) Dow Jones Newswires
July 17, 2019 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2023 to Apr 2024